The Dutch Competition Authority closes investigation into drug manufacturer after receiving assurances that it will not use its discount schemes to force hospitals into exclusive purchases (AbbVie)

ACM closes investigation into drug manufacturer AbbVie, competitors get more room now* Drug manufacturer AbbVie has stated that it will not force hospitals to purchase exclusively or to a large extent from AbbVie through discount schemes (or rebate programs). AbbVie has made these assurances following an investigation conducted by the Netherlands Authority for Consumers and Markets (ACM). This ensures that, once a patent has expired, there will be more room for new competing drugs (biosimilars). With these assurances with regard to AbbVie’s discount policy in tender processes, ACM has closed its investigation into anti-rheumatic drug Humira, and into possible abuse of a dominant position by AbbVie. Martijn Snoep, Chairman of the Board of ACM: “In general, competition should be freely

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Dutch Competition Authority, The Dutch Competition Authority closes investigation into drug manufacturer after receiving assurances that it will not use its discount schemes to force hospitals into exclusive purchases (AbbVie), 24 septembre 2020, e-Competitions October 2020, Art. N° 96990

Visites 78

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues